Login to Your Account

$25M to Dyax in 2008

Dyax Signs Sanofi to Antibody Deal Potentially Worth $500M

By Jennifer Boggs

Wednesday, February 13, 2008
While it awaits results from a confirmatory trial with hereditary angioedema drug DX-88, Cambridge, Mass.-based Dyax Corp. picked up another partner for its antibody platform, signing Sanofi-Aventis in a potential $500 million deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription